Clinical trials: HIV Seronegative
HIV Infections
Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
The purpose of the study is to determine the safety of mucosal immune responses to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
- Trial name
- NCT00955006
- Testing
- VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
A Study of GENEVAX-HIV, a Possible Vaccine
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug…
- Trial name
- NCT00002232
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
HIV Infections, Health Volunteers
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological sequelae associated with exposure to ABX464 and to explore selected immunological endpoints, compartmental pharmacokinetics, and…
- Trial name
- NCT02990325
- Testing
- ABX464 150mg, ABX464 50mg
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Abivax S.A.
Infections, Human Immunodeficiency Virus and Hepatitis
Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of HIV infection.
- Trial name
- NCT01467518
- Testing
- Dolutegravir, Methadone
- Where
- Canada
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort
The study of early, acute HIV infection is critical to understanding subtype-specific pathophysiologic differences, since up to 50% of acute HIV infections may be incapacitating.
- Trial name
- SEARCH004 (NCT00989144)
- Where
- Thailand
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
To evaluate, in healthy adult volunteers, the safety and immunogenicity of multivalent HIV-1 peptide immunogen, a formulation of HIV-1 gp120 principal neutralizing domain (PND) branched synthetic peptides from 15 viral strains…
- Trial name
- NCT00000795
- Testing
- HIV-1 Peptide Immunogen, Multivalent
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
The purpose of the study is to evaluate the safety, acceptability, and PK/PD profile of maraviroc gel following rectal and vaginal administration. The study also includes oral exposure to maraviroc.
- Trial name
- NCT02346084
- Testing
- Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally
This study is the first to try this product in the rectum of humans. This study is only to find out if the gel is safe for use in the rectum, not to see if the gel works.
- Trial name
- NCT00408538
- Testing
- UC-781 microbicide gel (0.1% and 0.25%)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV-1-infection, Hepatic Impairment
Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.
This is an open-label, parallel-group, nonrandomized, multi-centre, phase-IV, single dose trial in 8 HIV-seronegative subjects with severe hepatic impairment and 8 matched controls to assess the pharmacokinetics of a single dose…
- Trial name
- POLO (NCT03813979)
- Testing
- Dolutegravir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
HIV Infections
HIV Antiretroviral Drugs and Metabolism
Hypothesis 1: Ritonavir-based regimens increase triglycerides and VLDL by both increasing VLDL production and decreasing VLDL clearance.
- Trial name
- NCT00525239
- Testing
- ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections
Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide
Vaginal microbicides are compounds that may protect women from HIV and other sexually transmitted infections (STIs). This study will determine the safety of the microbicide UC-781 by comparing the effects of keeping the…
- Trial name
- NCT00441909
- Testing
- UC-781
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults
The purpose of this study is to evaluate the pharmacokinetics of dapivirine gel administered rectally to HIV-1 seronegative adults.
- Trial name
- NCT03393468
- Testing
- Dapivirine gel
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects
To evaluate an HIV synthetic lipopeptide candidate vaccine component, P3C541b, at two dose levels, administered subcutaneously (s.c.) in a randomized, double-blind, placebo controlled study.
- Trial name
- NCT00000845
- Testing
- P3C541b Lipopeptide
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Mental Health
Engaging Seronegative Youth to Optimize HIV Prevention Continuum
The focus of this study (Engaging Seronegative Youth to Optimize HIV Prevention Continuum) - will be to stop HIV-related risk acts and to encourage youth at high risk for HIV to adopt antiretroviral medications as treatment and…
- Conditions
- HIV, Mental Health, Substance Use, STI
- Trial name
- NCT03134833
- Testing
- Automated Messaging & Monitoring, Peer Support, Coaching
- Where
- 2 sites in United States
- Volunteers
- 1,478 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV Transmission, Transtheoretical Model of Change
Partner Services Pre-exposure Prophylaxis (PS-PrEP)
This study evaluates the feasibility (reach, adoption, safety and implementation) and initial efficacy (higher linkage to care) of the Partner Services Pre-exposure Prophylaxis (PS-PrEP) intervention versus phone based…
- Trial name
- PS-PrEP (NCT02749955)
- Testing
- PS-PrEP Intervention Group, PrEPLine Control Group
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- University of Chicago
HIV Infections
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
The purpose of this study is to evaluate the safety and pharmacokinetics of PC-1005 gel when used as a rectal microbicide in HIV-uninfected men and women (cis or transgender) with a history of consensual receptive anal…
- Trial name
- NCT03408899
- Testing
- PC-1005 gel
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
The purpose of this study is to measure the blood levels of amprenavir (APV) alone, APV combined with efavirenz (EFV), and APV/EFV combined with a third drug (nelfinavir [NFV], indinavir [IDV], ritonavir soft gel capsules [RTV…
- Trial name
- NCT00005762
- Testing
- Indinavir sulfate, Ritonavir, Amprenavir
- Where
- 8 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Positive, HIV Seronegative
CCTG 593: Testing and Linkage to Care
This is a CCTG sponsored project to determine if those recently screened for HIV would accept assistance to be linked into appropriate health services.
- Trial name
- NCT01941121
- Testing
- Linkage to PrEP or Care
- Where
- 3 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
HIV Infections
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in…
- Trial name
- NCT00002428
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical
HIV Infections, HIV Seronegativity
HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
The purpose of this study is to determine the best way to administer the candidate HIV vaccine, ALVAC HIV-1 (vCP205).
- Trial name
- NCT00013572
- Testing
- ALVAC-HIV MN120TMG (vCP205)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)